Published in Vaccine Weekly, June 4th, 2008
Researchers will present the latest data from the breadth of Pfizer's oncology portfolio, focused in four areas of discovery: anti-angiogenesis, signal transduction, immuno-oncology and cytotoxics/potentiators.
Metastatic Renal Cell Carcinoma (mRCC)
-- Updated overall survival data from a Phase 3 trial evaluating single-agent, oral SUTENT(R)...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly